Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraTSE:4540 -0.61%79 Pretax Margin % is 16.47% as of Mar. 2026, which is 2% below its 10-year median of 16.84. GuruFocus rates TSE:4540 with a GF Score™ of 79/100 and a GF Value™ of 円4,229.66 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Tsumura ranks better than 83.45% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Tsumura's Pre-Tax Income for the
three
months ended in Mar. 2026 was 円7,812 Mil. Tsumura's Revenue for the
three
months ended in Mar. 2026 was 円47,439 Mil. Therefore, Tsumura's pretax margin for the quarter that ended in Mar. 2026 was 16.47%.
The historical rank and industry rank for Tsumura's Pretax Margin % or its related term are showing as below:
TSE:4540'
s Pretax Margin % Range Over the Past 10 Years
Min: 14.95 Med: 16.84 Max: 25.16
Current: 21.31
TSE:4540's Pretax Margin % is ranked better than 83.45% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.06
vs TSE:4540: 21.31
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Tsumura Pretax Margin % Related Terms
Tsumura Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Tsumura's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Tsumura's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura (TSE:4540) has a Pretax Margin % of 16.47% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tsumura and its competitors. This is near median its historical median of 16.84. Over the past decade, Tsumura's Pretax Margin % has ranged from 14.95 to 25.16. According to the industry distribution chart, Tsumura ranks #159 out of 961 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Tsumura's Pretax Margin % too high?
Tsumura's current Pretax Margin % of 16.47% is near median its 10-year median of 16.84. Over the past 10 years, this metric has ranged from a low of 14.95 to a high of 25.16. The Drug Manufacturers industry median Pretax Margin % is 7.06. Tsumura's value of 16.47% is 133.3% above this industry median. Based on the distribution chart, Tsumura ranks #159 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tsumura has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tsumura's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #159 out of 961 companies for Pretax Margin %. This places Tsumura in the top 17% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.06. Tsumura's value of 16.47% is 133.3% above this benchmark. Historically, Tsumura's own Pretax Margin % has ranged from 14.95 to 25.16 over the past decade. While the company's 10-year median is 16.84 vs. the industry median of 7.06, Tsumura has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.06, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current Pretax Margin % of 16.47% is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tsumura and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current Pretax Margin % is 16.47%, which is near median its own 10-year median of 16.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Based on GuruFocus' analysis, Tsumura (TSE:4540) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,229.66, compared to a current price of 円3,767.00 — trading 10.9% below its estimated fair value. The current Pretax Margin % is 16.47%, which is near median its 10-year median of 16.84 and 133.3% above the Drug Manufacturers industry median of 7.06. Tsumura's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tsumura (TSE:4540), the current Pretax Margin % is 16.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (TSE:4540) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of 円3,767.00 is trading 10.9% below its estimated GF Value™ of 円4,229.66.
GuruFocus considers Tsumura to be Modestly Undervalued.
Key valuation signals for TSE:4540:
Pretax Margin %: 16.47% (near median its 10-year median of 16.84)
GF Value™: 円4,229.66 vs. price of 円3,767.00 (10.9% below fair value)
Industry Position: 133.3% above the Drug Manufacturers median (#159 of 961)
No single metric tells the full story. See the TSE:4540 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
79GF Score
Get the complete analysis for TSE:4540
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4540 has been successfully added to your 
